Rexahn Will Present Trial Results for Archexin at AACR

Rexahn Pharmaceuticals, Inc. (NYSE MKT:

), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that final data from the dose-escalation segment (Stage 1) of a Phase Ib/IIa clinical trial of Archexin® were presented at the 2016 American Association for Cancer Research Annual Meeting (AACR) in New Orleans, Louisiana. The Phase Ib/IIa clinical trial is evaluating Archexin, in combination with everolimus (a widely used chemotherapy drug) in patients with metastatic renal cell carcinoma (mRCC). The results were presented during the Late Breaking and Clinical Trials Session at AACR by Drs. S. Tagawa, G. Chatta, N. Agarwal and Rexahn scientists in a poster presentation entitled "Phase Ib/IIa Study of RX-0201 (Archexin®), A Novel Akt-1 Antisense Combined with Everolimus to Treat Metastatic Clear Cell Renal Carcinoma." "The results from the Archexin dose escalation clinical study are promising and offer an early signal of the potential safety and clinical activity of Archexin in combination with everolimus," commented Scott Tagawa, MD, MS, Medical Director of the Genitourinary Oncology Research Program at Weill Cornell Medicine. "The combination of Archexin and everolimus is rational based upon potential complementary mechanisms of action. While the primary objective of the initial dose escalation phase of the study was not intended to provide an efficacy evaluation, we nevertheless observed evidence of stable disease and tumor burden reduction in a significant number of patients in the study. When you consider that these are patients with very advanced disease, who have stopped responding to other therapies, we believe these data are especially encouraging."